The Securities and Exchange Commission has filed fraud charges against George Demos, a former Vice President of Drug Safety and Pharmacovigilance at Acadia Pharmaceuticals Inc., for trading on material, non-public information in advance of Acadia’s announcement of negative FDA news regarding its supplemental new drug application.  Acadia had secured prior approval of its drug to...Read More